Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.
复制标题
清道夫受体A类成员3（Scara3）在多发性骨髓瘤的疾病进展和耐药性中。
DOI：
10.1016/j.leukres.2013.03.004
复制
发表时间：
2013-08
影响因子：
2.7
通讯作者：
Goel A
中科院分区：
文献类型：
--
作者：
Brown CO;Schibler J;Fitzgerald MP;Singh N;Salem K;Zhan F;Goel A
本研究评估清道夫受体A类成员3（SCARA 3）在多发性骨髓瘤（MM）中的作用。SCARA3表达在用氧化应激物（电离辐射和化疗药物）处理后被诱导。在MM. 1S骨髓瘤细胞中观察到SCARA 3的表观遗传失活。地塞米松和硼替佐米对骨髓瘤细胞的杀伤作用受到SCARA3上调的抑制，而SCARA3敲低则使骨髓瘤细胞对药物敏感。临床样本显示SCARA3基因表达、骨髓瘤进展和良好的临床预后之间呈负相关。在MM中，SCARA 3可以防止氧化应激诱导的细胞杀伤，并可以作为MM进展和治疗反应的预测因子。
This study evaluates the role of scavenger receptor class A member 3 (SCARA3) in multiple myeloma (MM). SCARA3 expression was induced upon treatment with oxidative stressors (ionizing radiation and chemotherapeutic drugs). An epigenetic inactivation of SCARA3 was noted in MM.1S myeloma cells. Myeloma cell killing by dexamethasone and bortezomib was inhibited by up-regulation of SCARA3 while SCARA3 knockdown sensitized myeloma cells to the drugs. Clinical samples showed an inverse correlation between SCARA3 gene expression, myeloma progression, and favorable clinical prognosis. In MM, SCARA3 protects against oxidative stress-induced cell killing and can serve as predictor of MM progression and therapeutic response.
登录
查看更多内容
影响因子：
6.7
作者：
DeWitte-Orr SJ;Collins SE;Bauer CM;Bowdish DM;Mossman KL
通讯作者：
Mossman KL
影响因子：
6.7
作者：
Gangemi, Sebastiano;Allegra, Alessandro;Musolino, Caterina
通讯作者：
Musolino, Caterina
影响因子：
4.8
作者：
Mietus-Snyder, M;Gowri, MS;Pitas, RE
通讯作者：
Pitas, RE
影响因子：
4
作者：
Goel, Apollina;Spitz, Douglas R.;Weiner, George J.
通讯作者：
Weiner, George J.
DOI：
10.1084/jem.180.2.705
发表时间：
1994-08-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
de Villiers WJ;Fraser IP;Hughes DA;Doyle AG;Gordon S
通讯作者：
Gordon S